Real-world characteristics and survival outcomes of patients with metastatic <i>ALK</i> fusion-positive solid tumors treated with standard-of-care therapies
Data from this study suggest that ALK fusions have a negative prognostic effect in metastatic solid tumors and highlight the need for further investigation of ALK inhibitors in the tumor-agnostic setting.
Authors
- Sven Schwemmers
- Shirish M. Gadgeel (ORCID: https://orcid.org/0000-0001-5240-3811)
- Ritika Jagtiani
- Razelle Kurzrock (ORCID: https://orcid.org/0000-0003-4110-1214)
- Johannes Noé (ORCID: https://orcid.org/0000-0002-6563-2186)
- David M. Thomas (ORCID: https://orcid.org/0000-0002-2527-5428)
- Otto Fajardo (ORCID: https://orcid.org/0000-0002-3363-9287)
- Christos Nikolaidis (ORCID: https://orcid.org/0000-0001-7119-2562)
- Fabrice Barlési (ORCID: https://orcid.org/0000-0001-5793-3539)
- Jeong Eun Kim (ORCID: https://orcid.org/0000-0002-6927-3109)
Institutions
- Ulsan College (KR)
- Roche (Switzerland) (CH)
- Henry Ford Health System (US)
- Medical College of Wisconsin (US)
- Université Paris-Saclay (FR)
- UNSW Sydney (AU)
- University of Ulsan (KR)
- Molecular Oncology (United States) (US)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-03-29
- DOI
- https://doi.org/10.1093/oncolo/oyaf005
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Roche